Literature DB >> 16942666

Treatment options for chronic abdominal pain in children and adolescents.

Adrian Miranda1, Manu Sood.   

Abstract

Chronic abdominal pain is a common feature of most functional gastrointestinal disorders in children, including functional abdominal pain (FAP) and irritable bowel syndrome (IBS). FAP can impair a child's life and often leads to significant school absences. Although the underlying mechanism is likely multifactorial, early pain experiences during a vulnerable period in the developing nervous system can cause long-term changes in the brain-gut axis and ultimately may result in altered pain pathways and visceral hyperalgesia. Care providers often feel uncomfortable managing patients with chronic abdominal pain, as the pathophysiology is poorly understood, and limited data exist regarding safety and efficacy of therapeutic options in children. The primary goal of therapy in FAP is to alleviate pain symptoms and to help the child return to normal daily activities. Treatment should be individualized and chosen based on the severity of symptoms, the existence of comorbid psychological disorders, and the impact the disorder has on the child's school attendance and normal functioning. Various psychological interventions, such as cognitive-behavioral therapy, hypnosis, and guided imagery, have been successfully used in children with chronic abdominal pain. Pharmacologic therapies such as H(2) blockers, proton-pump inhibitors, tricyclic antidepressants, and various serotonergic drugs have been used, but good controlled trials are lacking. More studies are clearly needed to investigate the benefits and safety of pharmacologic therapy in children. Newer pharmacologic agents that target specific receptors involved in nociception, stress, and neurogenic inflammation currently are being developed. Future targets for visceral hyperalgesia should not only be aimed at alleviating symptoms but also should include prevention, particularly in cases with a suspected sensitizing event such as neonatal pain and postinfectious IBS.

Entities:  

Year:  2006        PMID: 16942666     DOI: 10.1007/BF02738530

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  31 in total

1.  The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors.

Authors:  Karla P Zeitz; Nicolas Guy; Annika B Malmberg; Sahera Dirajlal; William J Martin; Linda Sun; Douglas W Bonhaus; Cheryl L Stucky; David Julius; Allan I Basbaum
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

2.  Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways.

Authors:  Rie Suzuki; Sara Morcuende; Mark Webber; Stephen P Hunt; Anthony H Dickenson
Journal:  Nat Neurosci       Date:  2002-12       Impact factor: 24.884

Review 3.  Review article: tegaserod.

Authors:  M Camilleri
Journal:  Aliment Pharmacol Ther       Date:  2001-03       Impact factor: 8.171

4.  Long-term behavioral effects of repetitive pain in neonatal rat pups.

Authors:  K J Anand; V Coskun; K V Thrivikraman; C B Nemeroff; P M Plotsky
Journal:  Physiol Behav       Date:  1999-06

5.  Chronic abdominal pain in children: a clinical report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Authors:  Carlo Di Lorenzo; Richard B Colletti; Harold P Lehmann; John T Boyle; William T Gerson; Jeffrey S Hyams; Robert H Squires; Lynn S Walker; Pamela T Kanda
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-03       Impact factor: 2.839

6.  A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.

Authors:  J Tack; S Müller-Lissner; P Bytzer; R Corinaldesi; L Chang; A Viegas; S Schnekenbuehl; C Dunger-Baldauf; P Rueegg
Journal:  Gut       Date:  2005-07-14       Impact factor: 23.059

7.  Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.

Authors:  M C See; A H Birnbaum; C B Schechter; M M Goldenberg; K J Benkov
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

8.  The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.

Authors:  E A Mayer; S Berman; S W G Derbyshire; B Suyenobu; L Chang; L Fitzgerald; M Mandelkern; L Hamm; B Vogt; B D Naliboff
Journal:  Aliment Pharmacol Ther       Date:  2002-07       Impact factor: 8.171

9.  Recurrent abdominal pain and lactose absorption in children.

Authors:  E Lebenthal; T M Rossi; K S Nord; D Branski
Journal:  Pediatrics       Date:  1981-06       Impact factor: 7.124

10.  The use of dietary fiber in the management of simple, childhood, idiopathic, recurrent, abdominal pain. Results in a prospective, double-blind, randomized, controlled trial.

Authors:  W Feldman; P McGrath; C Hodgson; H Ritter; R T Shipman
Journal:  Am J Dis Child       Date:  1985-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.